for people ages 18-75 (full criteria)
at La Jolla, California and other locations
study started
estimated completion
Principal Investigator
by Eduardo Grunvald



The main purpose of the study is to assess the effect of LY3502970 in participants who have obesity or are overweight

Official Title

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities


Obesity Overweight and Obesity Overweight LY3502970 Dose 1 LY3502970 Dose 2 LY3502970 Dose 3 LY3502970 Dose 4


You can join if…

Open to people ages 18-75

  • Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
  • Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
  • Have had a stable body weight for the 3 months prior to randomization (not more than 5% body weight gain and/or loss)

You CAN'T join if...

  • Have any prior diagnosis of diabetes
  • Have a prior or planned surgical treatment for obesity
  • Have obesity induced by other endocrinological disorders or diagnosed monogenetic or syndromic forms of obesity
  • Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30 milliliter (mL)/minute (min)/1.73 m²
  • Have a history of acute chronic pancreatitis
  • Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 years Note: Participants with MDD or generalized anxiety disorder whose disease state is considered stable for the past 2 years and expected to remain stable throughout the course of the study, may be considered for inclusion if they are not on excluded medications.

Within 3 months prior to screening:

  • Have poorly controlled hypertension
  • Have history of acute myocardial infarction
  • Have history of cerebrovascular accident (stroke)
  • Had hospitalization due to congestive heart failure (CHF)
  • Have cancer
  • Have human immunodeficiency virus (HIV) and/or positive HIV antibodies historically or at screening
  • Have hepatitis B and/or positive hepatitis B surface antigen


  • UCSD - Altman Clinical and Translational Research Institute (ACTRI) not yet accepting patients
    La Jolla California 92037 United States
  • Anaheim Clinical Trials, LLC accepting new patients
    Anaheim California 92801 United States

Lead Scientist at UCSD

  • Eduardo Grunvald
    Clinical Professor, Medicine. Authored (or co-authored) 14 research publications.


accepting new patients
Start Date
Completion Date
Eli Lilly and Company
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Phase 2
Study Type
Last Updated